• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Aadi Bioscience Inc.

    3/18/25 9:29:27 AM ET
    $AADI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AADI alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001422142
    Aerpio Pharmaceuticals, Inc.
    ZETA ACQUISITION CORP II
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    Aadi Bioscience, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    Aadi Bioscience, Inc.
    Street Address 1 Street Address 2
    2 HEADQUARTERS PLAZA EAST BUILDING, 11TH FLOOR
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    MORRISTOWN NEW JERSEY 07960 551-321-2234

    3. Related Persons

    Last Name First Name Middle Name
    Lennon Dave
    Street Address 1 Street Address 2
    c/o Aadi Bioscience, Inc. 2 HEADQUARTERS PLAZA, E. BLDG, 11TH FL
    City State/Province/Country ZIP/PostalCode
    MORRISTOWN NEW JERSEY 07960
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Giacobello Scott
    Street Address 1 Street Address 2
    c/o Aadi Bioscience, Inc. 2 HEADQUARTERS PLAZA, E. BLDG, 11TH FL
    City State/Province/Country ZIP/PostalCode
    MORRISTOWN NEW JERSEY 07960
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Castelein Caley
    Street Address 1 Street Address 2
    c/o Aadi Bioscience, Inc. 2 HEADQUARTERS PLAZA, E. BLDG, 11TH FL
    City State/Province/Country ZIP/PostalCode
    MORRISTOWN NEW JERSEY 07960
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Desai Neil
    Street Address 1 Street Address 2
    c/o Aadi Bioscience, Inc. 2 HEADQUARTERS PLAZA, E. BLDG, 11TH FL
    City State/Province/Country ZIP/PostalCode
    MORRISTOWN NEW JERSEY 07960
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Aghazadeh Behzad
    Street Address 1 Street Address 2
    c/o Aadi Bioscience, Inc. 2 HEADQUARTERS PLAZA, EAST BUILDING, 11T
    City State/Province/Country ZIP/PostalCode
    MORRISTOWN NEW JERSEY 07960
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Dalal Anupam
    Street Address 1 Street Address 2
    c/o Aadi Bioscience, Inc. 2 HEADQUARTERS PLAZA, E. BLDG, 11TH FL
    City State/Province/Country ZIP/PostalCode
    MORRISTOWN NEW JERSEY 07960
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Hehenberger Karin
    Street Address 1 Street Address 2
    c/o Aadi Bioscience, Inc. 2 HEADQUARTERS PLAZA, E. BLDG, 11TH FL
    City State/Province/Country ZIP/PostalCode
    MORRISTOWN NEW JERSEY 07960
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Hirmand Mohammad
    Street Address 1 Street Address 2
    c/o Aadi Bioscience, Inc. 2 HEADQUARTERS PLAZA, E. BLDG, 11TH FL
    City State/Province/Country ZIP/PostalCode
    MORRISTOWN NEW JERSEY 07960
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Maroun Richard
    Street Address 1 Street Address 2
    c/o Aadi Bioscience, Inc. 2 HEADQUARTERS PLAZA, EAST BUILDING, 11T
    City State/Province/Country ZIP/PostalCode
    MORRISTOWN NEW JERSEY 07960
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Reeve Emma
    Street Address 1 Street Address 2
    c/o Aadi Bioscience, Inc. 2 HEADQUARTERS PLAZA, E. BLDG, 11TH FL
    City State/Province/Country ZIP/PostalCode
    MORRISTOWN NEW JERSEY 07960
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Zhao Baiteng
    Street Address 1 Street Address 2
    c/o Aadi Bioscience, Inc. 2 HEADQUARTERS PLAZA, E. BLDG, 11TH FL
    City State/Province/Country ZIP/PostalCode
    MORRISTOWN NEW JERSEY 07960
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Ball Bryan
    Street Address 1 Street Address 2
    c/o Aadi Bioscience, Inc. 2 HEADQUARTERS PLAZA, E. BLDG, 11TH FL
    City State/Province/Country ZIP/PostalCode
    MORRISTOWN NEW JERSEY 07960
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Dornan David
    Street Address 1 Street Address 2
    c/o Aadi Bioscience, Inc. 2 HEADQUARTERS PLAZA, E. BLDG, 11TH FL
    City State/Province/Country ZIP/PostalCode
    MORRISTOWN NEW JERSEY 07960
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-03-04    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number    None
    Jefferies LLC 2347
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    520 Madison Avenue
    City State/Province/Country ZIP/Postal Code
    New York NEW YORK 10022
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
    X All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $100,002,392 USD
    or    Indefinite
    Total Amount Sold $100,002,392 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    17

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $4,335,553 USD
    X Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Jefferies, LLC acting as placement agent.

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Aadi Bioscience, Inc. /s/ Steve Rodin Steve Rodin SVP and General Counsel 2025-03-17

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $AADI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AADI

    DatePrice TargetRatingAnalyst
    8/27/2024$5.00 → $1.75Overweight → Neutral
    Piper Sandler
    8/21/2024$11.00 → $1.50Buy → Hold
    Jefferies
    8/21/2024Buy → Hold
    TD Cowen
    12/15/2023Buy → Neutral
    H.C. Wainwright
    1/11/2022$45.00Buy
    Jefferies
    11/24/2021$47.00 → $49.00Buy
    HC Wainwright & Co.
    10/1/2021Outperform
    Cowen & Co.
    9/14/2021$51.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $AADI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Dalal Anupam was granted 1,561,000 shares (SEC Form 4)

      4 - Aadi Bioscience, Inc. (0001422142) (Issuer)

      3/5/25 7:51:57 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Castelein Caley was granted 1,666,000 shares (SEC Form 4)

      4 - Aadi Bioscience, Inc. (0001422142) (Issuer)

      3/4/25 7:24:11 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Zhao Baiteng was granted 1,250,000 shares (SEC Form 4)

      4 - Aadi Bioscience, Inc. (0001422142) (Issuer)

      3/4/25 6:14:13 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AADI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aadi Bioscience downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Aadi Bioscience from Overweight to Neutral and set a new price target of $1.75 from $5.00 previously

      8/27/24 7:14:32 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience downgraded by Jefferies with a new price target

      Jefferies downgraded Aadi Bioscience from Buy to Hold and set a new price target of $1.50 from $11.00 previously

      8/21/24 3:41:58 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience downgraded by TD Cowen

      TD Cowen downgraded Aadi Bioscience from Buy to Hold

      8/21/24 7:18:26 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AADI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Aadi Bioscience Inc.

      SC 13D/A - Aadi Bioscience, Inc. (0001422142) (Subject)

      10/1/24 5:35:56 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aadi Bioscience Inc.

      SC 13G - Aadi Bioscience, Inc. (0001422142) (Subject)

      9/3/24 5:51:01 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aadi Bioscience Inc.

      SC 13G - Aadi Bioscience, Inc. (0001422142) (Subject)

      8/28/24 4:42:02 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AADI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update

      MORRISTOWN, N.J., March 14, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, 2025. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com. About Aadi Bioscience  Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. Contact:[email protected]  View original content to download multimedia:https://w

      3/14/25 8:00:00 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Announces Closing of $100 Million PIPE Financing

      MORRISTOWN, N.J., March 4, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) ("Aadi"), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced the closing of its previously announced private placement. The private placement was led by Ally Bridge Group, with participation from new investors OrbiMed, Invus, Kalehua Capital and other accredited investors, Tae Han, co-founder of ProfoundBio, as well as existing investors, including Avoro Capital, KVP Capital and Acuta Capital Partners, for total gross proceeds of approximately $100 million. Aadi sold and issued an aggregate of 21,592

      3/4/25 4:05:00 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders

      MORRISTOWN, N.J., March 3, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced that the Company's stockholders have approved all proposals voted on at the Company's Special Meeting of Stockholders ("Special Meeting") held on February 28, 2025. Approved proposals include: Divestiture Proposal. The approval of the sale by Aadi to KAKEN INVESTMENTS INC. ("Kaken") of 100% of the outstanding shares of capital stock of Aadi Subsidiary, Inc. ("Aadi Sub") and thereby all or substantially all of Aadi's assets related to its FYARRO® (si

      3/3/25 8:00:00 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AADI
    SEC Filings

    See more

    $AADI
    Financials

    Live finance-specific insights

    See more
    • SEC Form S-8 filed by Aadi Bioscience Inc.

      S-8 - Whitehawk Therapeutics, Inc. (0001422142) (Filer)

      3/28/25 4:53:43 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)

      3/26/25 8:21:16 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Aadi Bioscience, Inc. (0001422142) (Filer)

      3/18/25 4:38:49 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update

      MORRISTOWN, N.J., March 14, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, 2025. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com. About Aadi Bioscience  Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. Contact:[email protected]  View original content to download multimedia:https://w

      3/14/25 8:00:00 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update

      LOS ANGELES, Oct. 30, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) today announced that it will report third quarter 2024 financial results and provide recent corporate updates on Wednesday, November 6, 2024. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com. About Aadi Bioscience  Aadi is a precision oncology company focused on the commercialization of FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). More information on the Company is available on the Aadi website at www.aadibio.com and connect with us on Twitter and L

      10/30/24 4:05:00 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update

      FYARRO® sales of $6.2 million for Q2 2024, a 15% quarter over quarter sales growth Interim analysis of two-thirds of fully enrolled PRECISION1 trial planned for Q3 2024 Conference call to be held today at 8:30 am EDT LOS ANGELES, Aug. 7, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent corporate progress. "The second quarter saw quarter over quarter sales growth for FYARRO, as anticipated, and an increase in demand across both new and ex

      8/7/24 8:00:00 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AADI
    Leadership Updates

    Live Leadership Updates

    See more
    • Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer

      Dr. Lennon brings over 20 years of pharmaceutical experience, including deep expertise in the development and commercialization of mTOR inhibitors Leadership transition expected to accelerate growth and leverage ground-breaking nanoparticle technology in FYARRO® to build a leading precision oncology company On track for interim analysis on 40 patients in tumor agnostic PRECISION1 trial in patients with TSC1/TSC2 alterations and trial initiations in endometrial and neuroendocrine cancers before the end of 2023 LOS ANGELES, Oct. 2, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a biopharmaceutical company focused on developing and commercializing precision therapies with mTOR pathwa

      10/2/23 8:00:00 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Announces Multiple Presentations on nab-Sirolimus at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

      LOS ANGELES, April 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the acceptance of abstracts for poster presentation at the upcoming 2023 ASCO Annual Meeting taking place June 2-6, 2023, in Chicago, IL.  The presentations will consist of a company-sponsored Trials-in-Progress (TIP) update from the PRECISION 1 Phase 2 study and combination data of nab-sirolimus and pazopanib (PAZO) from an ongoing Investigator Initiated Trial.    The details of the poster presentations are below: Title

      4/26/23 4:05:00 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research (AACR) Annual Meeting

      LOS ANGELES, April 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the presentation of three posters at the 2023 American Association for Cancer Research Annual Meeting (AACR), taking place April 14-19, 2023, in Orlando, FL. The presentations at AACR 2023 include: a trials-in-progress (TIP) poster for the ongoing PRECISION 1 trial, a registrational directed tumor agnostic study for patients with solid tumors driven by TSC1 or TSC2 alterations; results on the anti-tumor activity of nab-s

      4/14/23 1:09:00 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care